ASH 2021 | Salvage therapies superior to chemotherapy in post-transplant r/r cHL
Sanjal Desai, MBBS, Mayo Clinic, Rochester, MN, presents findings from a retrospective study assessing novel salvage therapies in patients with relapsed/refractory classic Hodgkin lymphoma (cHL) who have undergone autologous stem cell transplant (ASCT). 853 patients either received brentuximab vedotin (BV) with nivolumab, BV with bendamustine, BV monotherapy, gemcitabine-based chemotherapy, checkpoint inhibitors, or standard platinum-based chemotherapy. BV with nivolumab resulted in superior complete response and post-transplant progression-free survival rates compared with conventional chemotherapy, whereas BV with bendamustine only resulted in superior response rates. BV monotherapy had lower response rates compared to conventional chemotherapy. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.
